RaySearch Laboratories

RSNA is one of the world’s largest and most influential conferences in medical imaging and radiology. There, RaySearch will showcase several of its latest technological advancements, including:

• Image-guided liver ablation: RaySearch’s image-guided liver ablation module combines biomechanical deformable registration with deep-learning segmentation to support automatic delineation and precise target conformation for liver tumors. Built from RaySearch’s technology for radiation therapy, which is used in more than 1,000 clinics worldwide, the solution will offer a clinically evidenced streamlined workflow supporting improved progression-free survival in collaboration with The University of Texas MD Anderson Cancer Center. The result is a powerful and efficient solution that enables high-quality liver ablation treatments in just minutes.

• RayImaging^TM – next-generation radiology workstation: RaySearch will present its upcoming software, RayImaging, designed for advanced image viewing. RayImaging will include the essentials such as seamless PACS integration, flexible layouts, and support for displaying a broad range of medical images and DICOM objects. In addition to these core functions, the platform will also offer specialized tools, that have been built from the last 15 years of RaySearch's experience developing imaging software. These include rigid image registration and fusion, deformable registration algorithms, manual and automatic segmentation capabilities, and workflow automation with python scripting. In the future, RayImaging will become a complete package with support for reporting, automated workflows, integration with information systems, and more.

• Brachytherapy planning in RayStation®: External beam radiation therapy (EBRT) and brachytherapy planning are available within the same system. The brachytherapy module is fully integrated into RayStation, providing clinics with a unified environment for all modalities. It enables vendor-agnostic workflows for applicator modeling, EQD2 dose evaluation across modalities, scripting automation, and Monte Carlo dose computation in accordance with TG-186 guidelines.

• RayWorld – a unified vision for cancer care: RaySearch is continuing its journey to tie together its treatment planning system (RayStation®), oncology information system (RayCare®), oncology analytics system (RayIntelligence®), and new offerings in interventional and diagnostic radiology into a connected ecosystem. Attendees are invited to visit the RaySearch booth to see how this vision is already becoming reality today from advanced adaptive replanning in radiotherapy to chemotherapy quality control.

Additionally, RaySearch will display the ongoing development of DrugLog® – a cost-effective solution for quickly and efficiently verifying the identity and concentration of compounded injectable medications used, for example, in cancer treatment with cytostatic drugs (chemotherapy). DrugLog is intended for detection of errors in the preparation of drugs, which reduces the risk of medication errors. DrugLog will be a unique combination of cutting-edge software and reliable well-established hardware for absorption spectroscopy.

RaySearch will present a live session at the RSNA Innovation Theater titled “From Image-guided Ablation to Radiology Workstation: A Software Journey Towards Comprehensive Cancer Care”. The talk will be delivered by Tom Niessen, MSc, Technical Product Manager at RaySearch. Time & Location: The session will take place on Wednesday, 3 December 2025 at 14:30 CST, in Innovation Theater, Booth 3316 (South Hall A).

Johan Löf, founder and CEO, RaySearch: “The innovations we are presenting this year demonstrate how RaySearch is evolving beyond radiation oncology into comprehensive cancer care. From liver ablation planning to the development of our radiology workstation, we are building solutions that enable clinicians to work seamlessly across modalities. RSNA 2025 is an exciting opportunity to show what this future looks like.”

RayStation and RayCare are subject to regulatory clearance in some markets. RayStation v2025 SP1 is pending FDA 510(k) clearance and is not currently available for sale or clinical use in the United States. Image-guided ablation, DrugLog, and RayImaging are currently under development, not yet available for sale in the United States, and will require regulatory clearance before release.

For more information, please contact: 
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) 
Telephone: +46 (0) 8 510 530 00 

Matt Miley, Head of Marketing, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00

About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation® treatment planning system (TPS) and the oncology information system (OIS) RayCare®. The most recent addition to the RaySearch product line is RayIntelligence®. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RaySearch’s software has been sold to over 1,100 clinics in 47 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003 (STO: RAY B). More information is available at raysearchlabs.com.

Learn more about us on:
LinkedIn
YouTube